1. Academic Validation
  2. An exon-skipping mutation in the btk gene of a patient with X-linked agammaglobulinemia and isolated growth hormone deficiency

An exon-skipping mutation in the btk gene of a patient with X-linked agammaglobulinemia and isolated growth hormone deficiency

  • FEBS Lett. 1994 Jun 13;346(2-3):165-70. doi: 10.1016/0014-5793(94)00457-9.
B Duriez 1 P Duquesnoy F Dastot P Bougnères S Amselem M Goossens
Affiliations

Affiliation

  • 1 Laboratoire de Génétique Moléculaire INSERM U.91, Hôpital, Henri Mondor, Créteil, France.
Abstract

X-linked agammaglobulinemia (XLA) is an inherited immunodeficiency disease associated with a block in differentiation from pre-B to B cells. The XLA gene encodes a 659 Amino acids cytoplasmic protein tyrosine kinase named Btk (Bruton's tyrosine kinase). The few Btk gene alterations so far reported in XLA patients are heterogenous and distributed in all domains of the Btk protein. They appear to be responsible for a range of B cell immunodeficiency disorders of variable severity. Rare families in which XLA is inherited together with isolated growth hormone deficiency (IGHD) have been reported. Genetic analysis has shown that this disease association maps to the same region of the X chromosome as XLA, but whether the two phenotypes are caused by a common or different developmental or biochemical mechanism is unknown. We have analyzed the Btk gene of a patient with XLA and IGHD. RT-PCR analysis of Btk transcripts, sequencing data obtained from cDNA and genomic DNA and in vitro splicing assays showed that an intronic point mutation (1882 + 5G-->A) is responsible for skipping of an exon located in the tyrosine kinase domain. This exon-skipping event results in a frameshift leading to a premature stop codon 14 Amino acids downstream, and in the loss of the last 61 residues of the carboxy-terminal end of the protein. Although we studied a sporadic case, the results suggest that an alteration of the Btk gene might cause this unusual phenotype.

Figures